Jade Biosciences Q2 2026 net loss $55.8M; JADE101 Phase 1 data positive, cash $461M

Jade Biosciences, Inc.

Q2 2026 net loss $55.8M vs $32.1M in Q2 2025; R&D $50.1M, G&A $8.9M.
Cash, equivalents, investments $461.2M as of June 30, 2026; runway into Q4 2028 after $172.5M offering.
JADE101 Phase 1: ~70% mean IgA reduction after single 700mg dose; supports every-12-week dosing; Phase 2 JUNIPER underway, Phase 3 expected H1 2027.
JADE201 Phase 1 in rheumatoid arthritis dosing began; interim data 2027. JADE301 for dermatomyositis unveiled; Phase 1 healthy volunteers expected Q4 2026.
Mark Eisner, M.D., appointed to board; company advancing pipeline.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.